Is Shobunsha Holdings stock a buy today?

It is a hold for us. The stock trends above key moving averages and benefits from policy tailwinds, yet earnings growth is still uncertain. One composite grade reads B with a Hold stance, while another model flags a Sell. We would wait for PoC metrics or contract wins before upgrading.

How could MLIT’s hospital list update affect revenue?

It should raise demand for accurate maps, multilingual directions, and pharmacy data. That opens doors for data licensing, sponsored listings, and targeted ads tied to care and OTC searches. If agencies and partners embed these layers, Shobunsha could see steadier digital revenue into 2026 and beyond.

What price levels should investors watch now?

Near-term support is around ¥465, with resistance near ¥476 and the 2024-2025 year high at ¥510. The Bollinger mid-band sits close to ¥468.9. The 50-day average at ¥440.68 is a secondary support. Rising volume above the 8,304 average would add confidence on breakouts.

When is the next earnings announcement for Shobunsha?

The next scheduled earnings date is 2026-02-06. Timing can change, so we suggest checking company notices. Into that event, we will watch for updates on inbound medical PoCs, new data contracts, and any guidance on digital revenue mix and margins.

Global Market Insights

9475.T Stock Today, December 24: Inbound Medical PoC Momentum

ByHuzaifa Zahoor December 25, 2025December 25, 2025

Shobunsha Holdings stock is in focus today as Japan steps up inbound medical services. A recent government update and fresh hospital pilots point to real use cases for mapping, local search, and media. The latest snapshot shows shares near ¥472, with volume above average, and price trending above the 50-day line. We see growing interest after Tokyo began a PoC guiding visitors to clinics and OTC options, while Fujita Medical University launched an inbound CRM trial. For investors, 9475.T offers policy-linked optionality into 2026.